NCT06802835View on ClinicalTrials.gov

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

February 20, 2027

Study Completion Date

February 20, 2029

Conditions
Nasopharyngeal Cancinoma (NPC)Recurrent Nasopharynx CarcinomaMetastatic Nasopharyngeal Carcinoma
Interventions
DRUG

EGFR Antibody

6 cycles for combined therapy. Maintenance for 1 year.

DRUG

PD-1 antibody

6 cycles for combined therapy. Maintenance for 1 year.

DRUG

Gemcitabine, Cisplatin

6 cycles for combined therapy.

RADIATION

IMRT

IMRT for primary lesion

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06802835 - EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter